Sunday, June 3, 2018

CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday.


from Reuters: Health News https://ift.tt/2LdeQiE

Related Posts:

  • LATEST HEALTH NEWSGlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer. from Reuters: Health News https://ift.tt/2JrP1iV … Read More
  • LATEST HEALTH NEWS(Reuters Health) - For firefighters who worked at "Ground Zero" around September 11, 2001, a group of heart-disease risk factors also predicted who was likely to develop World Trade Center-related lung injury years later, res… Read More
  • LATEST HEALTH NEWSKentucky Attorney General Andy Beshear said on Thursday he had launched an investigation into allegations that pharmacy benefit managers (PBMs) had overcharged state health insurance programs for drugs and discriminated again… Read More
  • LATEST HEALTH NEWSSwimming is more demanding and burns more calories than a 30-minute land workout from Health https://ift.tt/2TER07m … Read More
  • LATEST HEALTH NEWSThe average BMI of men in white-collar jobs was 1.17 kg/m2 higher than those in blue-collar occupations from Health https://ift.tt/2T5n93I … Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner